AU2022282651A1 - Pemafibrate and/or tofogliflozin for use in treating liver disease - Google Patents

Pemafibrate and/or tofogliflozin for use in treating liver disease Download PDF

Info

Publication number
AU2022282651A1
AU2022282651A1 AU2022282651A AU2022282651A AU2022282651A1 AU 2022282651 A1 AU2022282651 A1 AU 2022282651A1 AU 2022282651 A AU2022282651 A AU 2022282651A AU 2022282651 A AU2022282651 A AU 2022282651A AU 2022282651 A1 AU2022282651 A1 AU 2022282651A1
Authority
AU
Australia
Prior art keywords
patient
score
pharmaceutically acceptable
acceptable salt
nash
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022282651A
Other languages
English (en)
Inventor
Noboru KANETA
Ryu Oshima
Shona Sanchita PENDSE
Ryohei TANIGAWA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Original Assignee
Kowa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd filed Critical Kowa Co Ltd
Publication of AU2022282651A1 publication Critical patent/AU2022282651A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022282651A 2021-05-27 2022-05-25 Pemafibrate and/or tofogliflozin for use in treating liver disease Pending AU2022282651A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163194088P 2021-05-27 2021-05-27
US63/194,088 2021-05-27
PCT/IB2022/054867 WO2022249071A1 (en) 2021-05-27 2022-05-25 Pemafibrate and/or tofogliflozin for use in treating liver disease

Publications (1)

Publication Number Publication Date
AU2022282651A1 true AU2022282651A1 (en) 2023-12-07

Family

ID=82020168

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022282651A Pending AU2022282651A1 (en) 2021-05-27 2022-05-25 Pemafibrate and/or tofogliflozin for use in treating liver disease

Country Status (10)

Country Link
US (1) US20240277745A1 (https=)
EP (1) EP4346809A1 (https=)
JP (1) JP2024520020A (https=)
KR (1) KR20240013203A (https=)
CN (1) CN117677385A (https=)
AU (1) AU2022282651A1 (https=)
BR (1) BR112023024701A2 (https=)
CA (1) CA3221073A1 (https=)
MX (1) MX2023013886A (https=)
WO (1) WO2022249071A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4556006A4 (en) * 2022-07-15 2026-01-07 Kowa Co MEDICATION TO LOWER LDL CHOLESTEROL IN THE BLOOD
CN115991682A (zh) * 2023-03-21 2023-04-21 广州佳途科技股份有限公司 一种培马贝特-d4的制备方法及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI696462B (zh) 2013-07-10 2020-06-21 日商興和股份有限公司 非酒精性脂肪性肝疾病治療劑
WO2018131626A1 (ja) 2017-01-11 2018-07-19 興和株式会社 非アルコール性脂肪性肝疾患の予防及び治療薬

Also Published As

Publication number Publication date
CN117677385A (zh) 2024-03-08
US20240277745A1 (en) 2024-08-22
WO2022249071A1 (en) 2022-12-01
KR20240013203A (ko) 2024-01-30
CA3221073A1 (en) 2022-12-01
EP4346809A1 (en) 2024-04-10
MX2023013886A (es) 2024-04-19
BR112023024701A2 (pt) 2024-02-15
JP2024520020A (ja) 2024-05-21

Similar Documents

Publication Publication Date Title
US12171731B2 (en) Methods and compositions for the treatment of steatosis-associated disorders
Hoffmann et al. Efficacy of 24-week Monotnerapy with Acarbose, Glibenclamide, or placebo in NIDDM patients: the Essen study
US20110195971A1 (en) Methods of identifying responders to dopamine agonist therapy
Lam et al. Acarbose in NIDDM patients with poor control on conventional oral agents: a 24-week placebo-controlled study
JP2018507914A (ja) 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法
EP4142770B1 (en) Semaglutide for the treatment of non-alcoholic steatohepatitis
US20160113953A1 (en) Method of treatment
EP4346809A1 (en) Pemafibrate and/or tofogliflozin for use in treating liver disease
CN119950682A (zh) 用于药物治疗的司美鲁肽
TW202114654A (zh) 包含如sglt 1/2抑制劑的sglt抑制劑之治療
US8445467B2 (en) Reducing risk of type 2 diabetes (T2D)
US20190161483A1 (en) Methods for using fxr agonists
US20220347190A1 (en) Treatment comprising fxr agonists
CA3034956C (en) TREATMENT OF NON-ALCOHOLIC HEPATIC STEATOSE
RU2781242C2 (ru) Способы лечения болезни гоше
HK40113179A (zh) 以回肠胆汁酸转运蛋白(ibat)抑制剂治疗以增加无事件存活期(efs)
HK40012462A (en) Treatment of nonalcoholic fatty liver disease
HK40012462B (en) Treatment of nonalcoholic fatty liver disease
TW201920269A (zh) IL-1β 結合抗體之用途
Capsules NDA 203858 Lomitapide Mesylate Capsules 5 mg, 10 mg, 20 mg Applicant: Aegerion Pharmaceuticals, Inc. Endocrinologic and Metabolic Drugs
Babura et al. Secondary Failure of Oral Hypoglycaemic Agents Among Type Two Diabetes Mellitus Patients Attending a Tertiary Health Facility in Northern Nigeria
Akram et al. The use of oral thiazoldinediones in correction of hormonal abnormalities among unmarried women with resistant PCO.